• Explore /
  • Poster
  • / Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).

Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).

Abstract Poster

Authors

Michal Sternschuss

Michal Sternschuss

Memorial Sloan Kettering Cancer Center, New York, NY

Michal Sternschuss , Nicolas Toumbacaris , Jeeban Paul Das , Thomas Powles , Dean F. Bajorin , Ritesh R Kotecha , Andrew Leonard Laccetti , Han Xiao , Emily Feld , Deaglan Joseph McHugh , Niamh M. Keegan , Samuel A Funt , Neil J. Shah , Gopa Iyer , David H Aggen , Min Yuen Teo , Irina Ostrovnaya , Jonathan E. Rosenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4581)

DOI

10.1200/JCO.2024.42.16_suppl.4581

Abstract #

4581

Poster Bd #

276

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

First Author: Shoma Yamamoto

First Author: Haojie Li

First Author: Helen H. Moon